To mark the 10th anniversary of the launch of the Health Policy & Technology journal, the HPT team, in partnership with the Fellowship of Postgraduate Medicine, is organising an online conference webinar series on key Health Policy and Technology themes of national and international interest.
Innovative health technologies are often enthusiastically viewed as game changers however their costs are sharply criticised. Take, for example, CAR T-Cell therapy, which has a price of up to 500,000 euro per person.
This raises many questions. For example, what is a fair price for a medicine? How should the price be related to the effectiveness or the number of end-users? What about the risks taken by the company to get the therapy to market? What about the risks taken by the end-user who use the medicine? And what about the risks taken by the payer? Is it unrealistic to think that there is a solution that would be fair to all stakeholders? And how can we ensure that the whole system is financially sustainable in the long term?
Carin Uyl De Groot – Director of the Institute for Medical Technology Assessment, Department of Health Care Policy and Management, Erasmus Medical Centre, Rotterdam, The Netherlands
Yannis Natsis is Policy Manager Universal Access and Affordable Medicines at the European Public Health Alliance (EPHA).
John LaMattina senior partner at PureTech Health and former president of Pfizer Global Research and Development
Joe Damond – Deputy Chief of Policy and Executive Vice President for International Affairs at the Biotechnology Innovation Organization (BIO)
Ken Redekop, Editor-in-Chief, Health Policy and Technology, Rotterdam, The Netherlands
Donald Singer, President, Fellowship of Postgraduate Medicine, London, UK